Skip to main content
x

Recent articles

A failed trial is a failed trial, says China’s regulator

The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.

A triple-negative breast cancer face-off

Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.

The month ahead: September’s upcoming events

It’s back to school for biotech, with a packed conference schedule.

Tidying up US stomach cancer approvals

A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.

Two oncology floats to end the summer break

Bicara and DualityBio will soon test market appetite for new oncology issues.

Insilico still feels the need for TEAD

Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.